A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
2011

Irinotecan and Chemotherapy for Colon Cancer

Sample size: 873 publication Evidence: low

Author Information

Author(s): Christos A Papadimitriou, Pavlos Papakostas, Maria Karina, Lia Malettou, Meletios A Dimopoulos, George Pentheroudakis, Epaminontas Samantas, Aristotelis Bamias, Dimosthenis Miliaras, George Basdanis, Nikolaos Xiros, George Klouvas, Dimitrios Bafaloukos, Georgia Kafiri, Irene Papaspirou, Dimitrios Pectasides, Charisios Karanikiotis, Theofanis Economopoulos, Ioannis Efstratiou, Ippokratis Korantzis, Nikolaos Pisanidis, Thomas Makatsoris, Fotini Matsiakou, Gerasimos Aravantinos, Haralabos P Kalofonos, George Fountzilas

Primary Institution: Hellenic Cooperative Oncology Group

Hypothesis

Does adding irinotecan to standard chemotherapy improve outcomes for stage II and III colon cancer patients?

Conclusion

Adding irinotecan to standard chemotherapy did not improve survival rates for stage II or III colon cancer but increased toxicity.

Supporting Evidence

  • The study included 873 eligible patients.
  • Patients were randomly assigned to two treatment arms.
  • The probability of overall survival at three years was 0.88 for Arm A and 0.86 for Arm B.
  • The probability of disease-free survival at three years was 0.78 for Arm A and 0.76 for Arm B.
  • Leucopenia and neutropenia were more common in patients receiving irinotecan.

Takeaway

This study looked at whether adding a drug called irinotecan to standard treatment helps people with colon cancer live longer. It found that it doesn't help but can make people feel worse.

Methodology

Patients were randomly assigned to receive either irinotecan with leucovorin and 5FU or leucovorin and 5FU alone, with a total of 873 patients included in the study.

Limitations

The study did not find significant differences in survival rates, and the addition of irinotecan increased toxicity.

Participant Demographics

Patients had histologically confirmed colon adenocarcinoma and were aged at least 18 years.

Digital Object Identifier (DOI)

10.1186/1741-7015-9-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication